Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.3%

3 terminated/withdrawn out of 232 trials

Success Rate

94.2%

+7.7% vs industry average

Late-Stage Pipeline

14%

33 trials in Phase 3/4

Results Transparency

4%

2 of 49 completed trials have results

Key Signals

39 recruiting2 with results

Enrollment Performance

Analytics

N/A
85(64.9%)
Phase 4
26(19.8%)
Phase 3
7(5.3%)
Phase 2
5(3.8%)
Early Phase 1
5(3.8%)
Phase 1
3(2.3%)
131Total
N/A(85)
Phase 4(26)
Phase 3(7)
Phase 2(5)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (232)

Showing 20 of 232 trials
NCT07450196Not Yet Recruiting

A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Valve Replacement for Type-0 Bicuspid Aortic Valve Stenosis Patients in China

Role: lead

NCT07529028Not ApplicableNot Yet Recruiting

Safety and Efficacy of the AbsnowTM II Absorbable Atrial Septal Defect Closure System for Atrial Septal Defect Closure Therapy

Role: collaborator

NCT07529938Completed

Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy

Role: lead

NCT07256197Phase 3Not Yet Recruiting

PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis

Role: collaborator

NCT05404880Active Not Recruiting

INSPIRIS China PMCF Study

Role: collaborator

NCT05320627Phase 4Completed

Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

Role: collaborator

NCT07462325Phase 4Not Yet Recruiting

Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease

Role: lead

NCT07054541Phase 4Not Yet Recruiting

A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire

Role: lead

NCT06901466Phase 4Recruiting

STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant

Role: lead

NCT07458672Not ApplicableNot Yet Recruiting

TAVR for Aortic Regurgitation Under TTE Guidance

Role: lead

NCT07007143Phase 4Recruiting

STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant

Role: lead

NCT07458724Not ApplicableCompleted

Radiation-free Anatomical Direct Imaging Approach for No-fluoroscopy Cardiac Electrode Implantation

Role: lead

NCT07453849Not ApplicableNot Yet Recruiting

TAVR for Aortic Regurgitation Under TEE Guidance

Role: lead

NCT07035847Not ApplicableRecruiting

Transaxillary TAVR With Solely Echocardiography Guidance

Role: lead

NCT07426107Not Yet Recruiting

Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization

Role: collaborator

NCT07308496Not ApplicableNot Yet Recruiting

Computed Tomography-derived Fractional Flow Reserve vs. Angiographic Quantitative Flow Ratio in Management of Patients With Coronary Artery Disease

Role: collaborator

NCT07398911Not ApplicableEnrolling By Invitation

3-Dimensional Simulation Guided Transcatheter Aortic Valve Replacement in Aortic Regurgitation(DIGITAL)

Role: collaborator

NCT07395843Completed

Clinical Feasibility of Full Free-Breathing Cardiac Magnetic Resonance Imaging

Role: lead

NCT07390513Active Not Recruiting

Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement

Role: lead

NCT07377149Not ApplicableNot Yet Recruiting

Improving the Quality of Coronary Artery Bypass Grafting

Role: collaborator